Agoracom Blog Home

Posts Tagged ‘CBD’

Avicanna $AVCN.ca $AVCNF Enters Multi-level Strategic Partnership with Al Harrington’s, Harrington Wellness Inc., to Commercialize re+PLAY™ Branded Products in Canada $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 8:46 AM on Tuesday, February 9th, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Development and licensing of a bespoke and evidence-based athletic line of CBD topical products for the re+PLAY brand in the U.S.
  • Avicanna to lead commercialization in Canada through consumer retail and medical sales channels.

TORONTO, Feb. 09, 2021 — Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an intellectual property licensing and royalty agreement with Harrington Wellness Inc. (“ Harrington Wellness” ) for the commercialization of a CBD topical product line targeting athletes and active consumers in Canada and the U.S. (the “ re+PLAY Agreement ”). 

Avicanna and Harrington Wellness have worked together extensively on researching, developing and optimizing a bespoke line of CBD-based topicals designed specifically for the athletic and sports community (the “ re+PLAY Products” ). These CBD-based topicals utilize Avicanna’s proprietary deep tissue technology for cannabinoid delivery and have been curated with the support of Harrington Wellness’ deep understanding of the needs of professional athletes. The products are planned to be launched in Q2 2021 in the United States by Harrington Wellness across retail and e-commerce channels and in Canada through medical and adult-use/consumer retail cannabis sales channels by Avicanna. The product formulations are also enrolled in several preclinical studies with leading Canadian medical institutions to assess their efficacy in chronic pain and osteoarthritis. 

Under the re+PLAY Agreement, which has an initial three-year term, Avicanna has licensed the use of certain proprietary product formulations to Harrington Wellness to be used in connection with the manufacture and distribution of the re+PLAY Products in the United States. Additionally, Harrington Wellness has also licensed the use of the re+PLAY brand to Avicanna to be used in connection with the manufacture and distribution of the re+PLAY Products in Canada. The re+PLAY Products will be branded and sold under the re+PLAY brand in both the United States and Canada. Royalties are payable to Avicanna and Harrington Wellness as consideration for each of the licenses. 

“As a former professional athlete myself and avid CBD user, I understand the importance of being in peak physical condition and finding products that help you to recover faster,” says Al Harrington, CEO of Harrington Wellness. “Avicanna has been an incredible partner in developing the re+PLAY formulas and expanding the product line’s availability into Canada.” 

In commenting on the re+PLAY Agreement, Aras Azadian, CEO of Avicanna said, “I am thrilled to finally introduce our relationship with Al Harrington and Harrington Wellness. This partnership was formed on the alignment of the vision to introduce premium and scientifically backed products for athletic and active consumers to the market. Additionally, the distinct expertise of the two companies and collaborative spirit has yielded an advanced and evidence-based line of products that are tailored to promote a healthy active lifestyle for the athlete in all of us.” 

To the knowledge of the Company, it is in compliance with all applicable laws in the jurisdictions in which it operates. 

About Harrington Wellness  

Founded in 2018 by Viola CEO and NBA Vet, Al Harrington, Harrington Wellness produces a wide range of products via in house manufacturing, joint venture projects and white label arrangements with other vetted organizations that stand for the highest quality and reliable medical benefits. These items are sold online via in house and existing marketplace sites, in brick and mortar retail and by health professions directly in their clinics. 

Harrington Wellness’ hero brand, re+PLAY™ is a performance based CBD wellness brand created with the combined knowledge and experience of athletes, doctors, and certified athletic trainers. Our team is dedicated to creating best in class products that deliver the powerful healing properties of the plant to our customers. All products are made using a triple-tested process with hemp grown in the USA, and are free of heavy metals, pesticides, and harmful microbes. 

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/754961-avicanna-enters-multi-level-strategic-partnership-with-al-harrington-s-harrington-wellness-inc-to-commercialize-re-play-branded-products-in-canada/messages/2302800#message

VIDEO – Hollister $HOLL.ca $HSTRF Reported Record Q4 Revenues of CAD $14.93M From 370 Dispensaries In California and Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 7:42 PM on Sunday, January 31st, 2021
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences (HOLL:CSE) is a multi-state operator with multiple, high-quality products that are now carried in over 280 dispensaries throughout California and over 90 dispensaries throughout Arizona.

Q4 Highlights:

  • Record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA

Venom Extracts is their 100% owned subsidiary that is absolutely dominating the state of Arizona.  More than just lip service:

  • Since the closing (Venom), in the three quarters following, Venom contributed approximately CDN$38 million to the company’s 2020 revenue. 
  • In the entire year of 2020,
    • Venom generated greater than CDN$ 40 million in revenue (and CDN$ 4.9 million in adjusted EBITDA),
    • Up from CDN$ 16.4 million in 2019 a 144% year over year revenue increase, and ending the year with a record month of sales for December totaling approximately CDN$5.5 million .
  • Sold over 4 million grams of product in 2020
    • accounting for up to 30 percent of category sales statewide in Arizona .
  • Positioned for continued growth in Arizona with the recently passed adult-use legislation
  • Marijuana Business Daily projects that Arizona’s recreational market could generate up to $400 million in revenue its first year and more than $700 million by 2024.
  • ….. And it is run by the absolute coolest guy in small cap Cannabis – Jake Cohen  

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Avicanna $AVCN.ca $AVCNF Launches RHO Phyto™ Topical Gels in Canada and Initiates Clinical Studies $TRUL.ca $ACB

Posted by AGORACOM-JC at 7:59 AM on Thursday, January 28th, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • RHO Phyto Deep Tissue Gels will be initially available on the Medical Cannabis by Shoppers Drug Mart™ online platform and expanded into specific consumer retail channels in February 2021.
  • Initiation of osteoarthritis preclinical trials in Canada in addition to the enrollment of the products into the UHN MC-RWE study to evaluate the effectiveness on pain, sleep, anxiety, and depression.

TORONTO, Jan. 28, 2021 — Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce the launch of the RHO Phyto™ Deep Tissue Gels (the “ RHO Phyto Deep Tissue Gels ”) through Medical Cannabis by Shoppers Drug Mart as well as through additional adult use channels. The Company is also pleased to announce the initiation of pre-clinical osteoarthritis evaluations after successful in vitro studies and the enrollment of the Deep Tissue Gels in the Medical Cannabis Real World Evidence (“ MC-RWE ”) study. The MC-RWE study is led by the University Health Network (“ UHN ”) with the goal to evaluate the effectiveness of medical cannabis on pain, sleep and other related comorbidities.

About the RHO Phyto Deep Tissue Gels

The RHO Phyto Deep Tissue Gels synergistically combine natural clove oil and menthol with cannabinoids and natural polyphenols in advanced emulsions which are optimized for faster absorption and deeper delivery. The RHO Phyto Deep Tissue Gel formulations are also designed for long term cannabinoid shelf-life stability and accurate dosing with cooling sensation, and pleasant mint aroma. The deep tissue technology has been developed and optimized by Avicanna’s research and development team. Over the last 3 years, the RHO Phyto Deep Tissue Gel formulations have been validated by a series of preclinical studies where both stability and enhanced absorption into the deeper layers of the skin were shown.

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/754105-avicanna-launches-rho-phyto-topical-gels-in-canada-and-initiates-clinical-studies/messages/2300727#message

Hollister Biosciences Inc. $HOLL.ca $HSTRF Commends the State of Arizona for starting Adult-Use Cannabis Sales ahead of schedule, Venom Extracts it’s 100% owned subsidiary is a category leader with over 4 million grams sold throughout the state in 2020 $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 8:21 AM on Monday, January 25th, 2021
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Branded Products now on sale in over 370 cannabis dispensaries in Arizona and California
  • 4 owned brands, and 3 brand collaborations
  • Over 4 million grams sold
  • Over 96,000 lbs. of cannabis biomass converted into finished products in Arizona
  • Total sales for 2020 increased 3233% from 2019 and are estimated to be approximately CDN $40 million
  • December 2020 sales totaled greater than CDN$6 million

VANCOUVER, BC , Jan. 25, 2021 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, “Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 98 dispensaries throughout Arizona , is pleased to commend the state of Arizona for its efficient activation of adult-use cannabis sales. Legal sales of adult use cannabis in Arizona commenced mid-day on Friday January 22 nd , 2021, several months ahead of industry expectations, and the fastest that any of the 15 states with recreational marijuana has gone from voter approval to actual sales.

The company’s wholly owned subsidiary, Venom Extracts (” Venom “) product suite is a category leader with over 4 million grams sold in 2020, accounting for up to 30 percent of category sales state-wide. Venom is positioned for continued growth in Arizona , it has a strong brand recognition and distribution network, its products are available at leading retailers including Harvest Health and Recreation (CSE: HARV , OTCQX: HRVSF ), Curaleaf (CSE: CURA , OTCQX: CURLF ), Bloom, MuV and Oasis Cannabis dispensaries among others.

Arizona voted to legalize adult use cannabis in November, “Marijuana Business Daily projects that the state’s recreational market could generate up to $400 million in revenue its first year and more than $700 million by 2024”.

Read More: https://agoracom.com/ir/HollisterBiosciences/forums/discussion/topics/753842-hollister-biosciences-inc-commends-the-state-of-arizona-for-starting-adult-use-cannabis-sales-ahead-of-schedule-venom-extracts-it-s-100-owned/messages/2300014#message

Innocan Pharma $INNO.ca Announces Successful Production of #CBD Loaded Liposomes under Aseptic Conditions $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:57 AM on Friday, January 22nd, 2021
Innocan-Blog
  • Announced today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.
  • This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.

Herzliya, Israel and Calgary, Alberta–(January 22, 2021) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the “Company” or “Innocan“), is pleased to announce today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.

This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.

This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan’s CBD-loaded LPT in relevant diseases. These studies follow the results of previous studies that demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection.

The previous study, led by Dr. Ahuva Cern, Senior Researcher in the laboratory of Professor Barenholz at the Hebrew University in Jerusalem, found significant amounts of CBD in the blood and muscles of mice up to 21 days after a single intramuscular injection of CBD using the LPT. The same findings were also demonstrated in rats.

Read More: https://agoracom.com/ir/InnocanPharma/forums/discussion/topics/753657-innocan-pharma-announces-successful-production-of-cbd-loaded-liposomes-under-aseptic-conditions/messages/2299445#message

Hollister Biosciences Inc. $HOLL.ca $HSTRF Announces an Increase in Private Placement to $6.5 Million $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 12:46 PM on Thursday, January 21st, 2021
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

  • Announced that it has entered into an amended letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has now agreed to offer for sale, together with a syndicate of agents 17,810,000 Special Warrants of the Company on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.365 for total gross proceeds of up to $6,500,650
  • Each Special Warrant shall be automatically exercisable into units of the Company, as described below. Each Unit shall consist of one common share of the Company and one-half of one common share purchase warrant

VANCOUVER, British Columbia, Jan. 21, 2021 — Hollister Biosciences Inc. (CSE:HOLL, OTC:HSTRF, FRANKFURT:HOB) (“ Hollister ” or the “ Company ”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has now agreed to offer for sale, together with a syndicate of agents (together with Eight Capital, the “ Agents ”), 17,810,000 Special Warrants of the Company (the “ Special Warrants ”), on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.365 (the “ Issue Price ”) for total gross proceeds of up to $6,500,650 (the “ Offering ”).

Each Special Warrant shall be automatically exercisable into units of the Company (the “ Units ”), as described below. Each Unit shall consist of one common share of the Company (a “ Share ”) and one-half of one common share purchase warrant (each full warrant, a “ Warrant ”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $0.50 per Share for a period of 46 months following the Closing Date.

Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “ Automatic Exercise Date ”) that is the earlier of: (i) the date that is three business days following the date on which the Company either (A) obtains a receipt from the applicable securities regulatory authorities (the “ Securities Commissions ”) for a (final) short form prospectus qualifying distribution of the Units underlying the Special Warrants (the “ Qualifying Prospectus ”); or (B) files a supplement to a (final) short form base shelf prospectus qualifying the distribution of the Units underlying the Special Warrants (the “ Qualifying Supplement ”), and (ii) the date that is four months and one day after the Closing of the Offering.

Read More: https://agoracom.com/ir/HollisterBiosciences/forums/discussion/topics/753581-hollister-biosciences-inc-announces-an-increase-in-private-placement-to-6-5-million/messages/2299280#message

Avicanna $AVCN.ca $AVCNF Initiates Pre-Clinical and Behavioural Studies on its RHO Phyto™ Formulary with University of Guelph and Provides Research and Management Team Updates $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 8:07 AM on Thursday, January 21st, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia.
  • Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.

TORONTO, Jan. 21, 2021– Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products has updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia. Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.

Initiation of pre-clinical studies on RHO Phyto in collaboration with University of Guelph

Further to Avicanna’s previous announcement regarding Dr. Khokhar’s research team at the University of Guelph being awarded a Natural Sciences and Engineering Research Council of Canada (“ NSERC ”) Alliance grant focused on the neurobiological underpinnings of cannabis toxicosis with the aim to evaluate Avicanna’s formulations in the treatment of cannabis-induced toxicosis, the project is now being expanded. The expansion of the project includes pharmacokinetic and behavioural testing of Avicanna’s RHO Phyto™ formulations as well as studying their efficacy in alleviating neuropathic pain and addiction. The data generated from the research will help guide Avicanna’s clinical development, including the pharmaceutical and real-world evidence studies related to the RHO Phyto formulations, and will provide additional information to health care practitioners who are recommending and prescribing the products in several markets.

COVID-19 drug candidate project update

The research collaboration with the University of Toronto on the development of a drug candidate to treat lung inflammation caused by COVID-19, with funding support from an NSERC Alliance grant and a MITACS Alliance grant, is complete. The peer-reviewed grants were focused on the development of a cannabinoid formulation to be used for further research on COVID-19. The physical and chemical characterization of the optimized cannabinoid formulation is complete, which included its stability and drug release properties in relevant conditions.

COVID-19 and anti-inflammatory related research collaboration with TRU with non-dilutive funding

In partnership with Avicanna, Dr. Kingsley Donkor and collaborators from Thompson Rivers University (” TRU ”), will be evaluating naturally derived cannabinoids and candidate formulations for their efficacy to modulate the receiving receptor of COVID-19 (angiotensin-converting ACE2 gene expression). This project will focus on elucidating the mechanism of action of novel prophylactic nasal and oral cannabinoid products for humans that target ACE2 viral gateways. Candidate formulations, once identified, will be evaluated for anti-inflammatory effects in human-derived lung tissue models. The research with TRU is supported by an NSERC grant and a MITACS Internship.

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/753556-avicanna-initiates-pre-clinical-and-behavioural-studies-on-its-rho-phyto-formulary-with-university-of-guelph-and-provides-research-and-management/messages/2299215#message

Innocan Pharma $INNO.ca Successfully Completes Large Scale Production of Exosomes $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, January 14th, 2021
Innocan-Blog
  • Announced the successful completion of a large-scale production of exosomes
  • Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
  • Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
  • This achievement is expected to pave the way for larger tests and studies.

Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.

“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.

Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.

Hollister Biosciences Inc. $HOLL.ca $HSTRF Provides Update on Q4 2020 Performance Including CDN $14.93 Million in Revenue With an Estimated CDN $2.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019 $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 7:44 AM on Friday, January 8th, 2021
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • For the period beginning October 1 st , 2020 and ending December 31 st , 2020, Hollister reports that it generated record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products.
  • “We are very pleased with our ability to deliver record quarterly revenue in such a challenging market environment. We attribute our revenue growth to further penetration of the California and Arizona dispensary networks and successful new product launches with our joint venture partners. Sales of cannabis related products continue to show resilience throughout the COVID-19 pandemic. We hope to continue this positive momentum into 2021” stated Alex Somjen , President.

VANCOUVER, BC , Jan. 7, 2021 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 90 dispensaries throughout Arizona , is pleased to provide an update on its Q4, 2020 performance.

Q4 2020 Update

For the period beginning October 1 st , 2020 and ending December 31 st , 2020, Hollister reports that it generated record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.

“We are very pleased with our ability to deliver record quarterly revenue in such a challenging market environment. We attribute our revenue growth to further penetration of the California and Arizona dispensary networks and successful new product launches with our joint venture partners. Sales of cannabis related products continue to show resilience throughout the COVID-19 pandemic. We hope to continue this positive momentum into 2021” stated Alex Somjen , President.

Read More: https://agoracom.com/ir/HollisterBiosciences/forums/discussion/topics/752594-hollister-biosciences-inc-provides-update-on-q4-2020-performance-including-cdn-14-93-million-in-revenue-with-an-estimated-cdn-5-53-million-in/messages/2296579#message

Thoughtful Brands $TBI.ca Announces Binding Letter of Intent for Reverse-Takeover of Franchise Cannabis $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM at 3:02 PM on Thursday, January 7th, 2021
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/Throught_brands_logo.png
  • Franchise Cannabis, a leading European medical cannabis company, to complete public listing with strategic expansion into other cannabis markets.
  • Combined company will be well positioned to expand product offerings and distribution channels in the US and Europe.

Thoughtful Brands Inc. (“TBI“) (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) and Franchise Cannabis Corp. (“FCC“) are pleased to announce that they have entered into a binding letter of intent (the “Letter of Intent“), dated January 6, 2021, to consummate a going-public transaction for FCC involving the reverse-takeover of TBI (the “Transaction“).

The Transaction will involve the acquisition of all of the outstanding share capital of FCC by TBI, with the resulting Canadian reporting company being listed on the Canadian Securities Exchange (the “CSE“) under the name “Franchise Cannabis Corp.” (the “Resulting Issuer“). The Transaction is expected to be highly-accretive as both companies look to build on their complementary expertise to grow their respective businesses within the United States and Europe.

RESULTING ISSUER FOOTPRINT

Following completion of the Transaction, the Resulting Issuer, through its operating subsidiaries will have two German medical cannabis distribution businesses, a registered cannabis genetics subsidiary in Denmark, cultivation and strategic supply agreements on three continents, and a rapidly growing pharmaceutical distribution business with sales to over 18 countries combined with a high revenue CBD eCommerce platform. In addition, the Resulting Issuer will have a US based CBD extraction facility. Together TBI and FCC remain devoted to building on the growing pharmaceutical distribution platform in Europe while expanding sales channels through its regulated medical cannabis business in Europe and the consumer-focused CBD eCommerce division in North America and expansion to Europe. Management believes the combined companies’ assets are synergistic as they combine expertise and access to the two largest medical cannabis and consumer CBD markets, being the United States and Europe.

Read More: https://agoracom.com/ir/ThoughtfulBrands/forums/discussion/topics/752558-thoughtful-brands-announces-binding-letter-of-intent-for-reverse-takeover-of-franchise-cannabis/messages/2296520#message